WallStSmart

Boston Scientific Corp (BSX)vsKoninklijke Philips NV ADR (PHG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 16% more annual revenue ($20.61B vs $17.83B). BSX leads profitability with a 17.3% profit margin vs 5.0%. PHG appears more attractively valued with a PEG of 0.32. BSX earns a higher WallStSmart Score of 71/100 (B).

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9

PHG

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 5.0Value: 7.3Quality: 5.3
Piotroski: 6/9Altman Z: 1.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-23.3%)

Margin of Safety

-23.3%

Fair Value

$46.11

Current Price

$56.50

$10.39 premium

UndervaluedFair: $46.11Overvalued
PHGUndervalued (+3.8%)

Margin of Safety

+3.8%

Fair Value

$33.33

Current Price

$26.16

$7.17 discount

UndervaluedFair: $33.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$83.97B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

PHG3 strengths · Avg: 8.7/10
PEG RatioValuation
0.3210/10

Growing faster than its price suggests

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.31B8/10

Generating 1.3B in free cash flow

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

PHG4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.1%4/10

1.1% revenue growth

Return on EquityProfitability
7.8%3/10

ROE of 7.8% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

EPS GrowthGrowth
-0.5%2/10

Earnings declined 0.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : PHG

The strongest argument for PHG centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.32 suggests the stock is reasonably priced for its growth.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : PHG

The primary concerns for PHG are Revenue Growth, Return on Equity, Profit Margin.

Key Dynamics to Monitor

BSX profiles as a mature stock while PHG is a value play — different risk/reward profiles.

PHG carries more volatility with a beta of 0.92 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

PHG generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (71/100 vs 51/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Koninklijke Philips NV ADR

HEALTHCARE · MEDICAL DEVICES · USA

Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.

Want to dig deeper into these stocks?